EE200300248A - GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon - Google Patents

GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon

Info

Publication number
EE200300248A
EE200300248A EEP200300248A EEP200300248A EE200300248A EE 200300248 A EE200300248 A EE 200300248A EE P200300248 A EEP200300248 A EE P200300248A EE P200300248 A EEP200300248 A EE P200300248A EE 200300248 A EE200300248 A EE 200300248A
Authority
EE
Estonia
Prior art keywords
combination
dehydrogenase inhibitors
sorbitol dehydrogenase
gaba agonists
gaba
Prior art date
Application number
EEP200300248A
Other languages
English (en)
Inventor
Lakshman Mylari Banavara
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300248A publication Critical patent/EE200300248A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200300248A 2000-11-30 2001-11-19 GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon EE200300248A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
EE200300248A true EE200300248A (et) 2003-10-15

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300248A EE200300248A (et) 2000-11-30 2001-11-19 GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon

Country Status (38)

Country Link
US (1) US6544998B2 (et)
EP (1) EP1337271B1 (et)
JP (1) JP2004514699A (et)
KR (1) KR20030059290A (et)
CN (1) CN1477975A (et)
AP (1) AP2001002360A0 (et)
AR (1) AR031431A1 (et)
AT (1) ATE281181T1 (et)
AU (1) AU2002215159A1 (et)
BG (1) BG107774A (et)
BR (1) BR0115783A (et)
CA (1) CA2430298A1 (et)
CR (1) CR6964A (et)
CZ (1) CZ20031399A3 (et)
DE (1) DE60106968T2 (et)
DO (1) DOP2001000289A (et)
EA (1) EA200300432A1 (et)
EC (1) ECSP034624A (et)
EE (1) EE200300248A (et)
ES (1) ES2230378T3 (et)
HR (1) HRP20030420A2 (et)
HU (1) HUP0302160A3 (et)
IL (1) IL155704A0 (et)
IS (1) IS6786A (et)
MA (1) MA26964A1 (et)
MX (1) MXPA03004870A (et)
NO (1) NO20032441L (et)
OA (1) OA12534A (et)
PA (1) PA8534101A1 (et)
PE (1) PE20020597A1 (et)
PL (1) PL365927A1 (et)
PT (1) PT1337271E (et)
SK (1) SK6192003A3 (et)
SV (1) SV2003000751A (et)
TN (1) TNSN01169A1 (et)
UY (1) UY27042A1 (et)
WO (1) WO2002043762A2 (et)
ZA (1) ZA200303381B (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
SK286227B6 (sk) * 2001-05-25 2008-05-06 Warner-Lambert Company Llc Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
CA2560995A1 (en) * 2004-04-02 2005-10-20 Impax Laboratories, Inc. Controlled release dosage for gaba receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
ES2528674T3 (es) 2005-02-17 2015-02-11 Astellas Pharma Inc. Piperidina y carboxilatos de piperacina como inhibidores de FAAH
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
DK2142529T3 (da) 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
JP5452494B2 (ja) * 2007-10-09 2014-03-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンフォチアミンと１または２種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
CA2837178C (en) 2011-06-22 2016-09-20 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
JP2022531466A (ja) * 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
DK153787C (da) 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
DE60009777T2 (de) * 1999-04-01 2004-08-19 Pfizer Products Inc., Groton Verbindung für Behandlung und Vorsorge bei Diabetes
EP1185275A1 (en) * 1999-04-01 2002-03-13 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
NO20032441D0 (no) 2003-05-28
BG107774A (en) 2004-01-30
CZ20031399A3 (cs) 2004-04-14
SK6192003A3 (en) 2004-07-07
PA8534101A1 (es) 2002-10-31
HRP20030420A2 (en) 2004-08-31
ZA200303381B (en) 2004-04-30
MA26964A1 (fr) 2004-12-20
PE20020597A1 (es) 2002-07-08
KR20030059290A (ko) 2003-07-07
IL155704A0 (en) 2003-11-23
CR6964A (es) 2004-02-02
CN1477975A (zh) 2004-02-25
HUP0302160A3 (en) 2005-05-30
DE60106968D1 (de) 2004-12-09
SV2003000751A (es) 2003-01-13
AP2001002360A0 (en) 2001-12-31
US20020091128A1 (en) 2002-07-11
AR031431A1 (es) 2003-09-24
OA12534A (en) 2006-06-05
WO2002043762A3 (en) 2003-03-13
EP1337271B1 (en) 2004-11-03
WO2002043762A2 (en) 2002-06-06
PL365927A1 (en) 2005-01-10
MXPA03004870A (es) 2003-08-19
ATE281181T1 (de) 2004-11-15
IS6786A (is) 2003-04-14
EA200300432A1 (ru) 2003-10-30
BR0115783A (pt) 2003-09-16
ECSP034624A (es) 2003-07-25
US6544998B2 (en) 2003-04-08
TNSN01169A1 (fr) 2005-11-10
EP1337271A2 (en) 2003-08-27
HUP0302160A2 (hu) 2003-11-28
PT1337271E (pt) 2005-01-31
UY27042A1 (es) 2002-07-31
ES2230378T3 (es) 2005-05-01
CA2430298A1 (en) 2002-06-06
DOP2001000289A (es) 2003-02-15
DE60106968T2 (de) 2005-11-03
NO20032441L (no) 2003-07-03
AU2002215159A1 (en) 2002-06-11
JP2004514699A (ja) 2004-05-20

Similar Documents

Publication Publication Date Title
EE200300248A (et) GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon
EE200300249A (et) GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon
CY2015053I1 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
EE200200576A (et) Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
GB0025782D0 (en) Use of inhibitors
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
EE200300134A (et) Uued tiadiasoolid ja oksadiasoolid ning nende kasutamine fosfodiesteraas-7 inhibiitoritena
ATE253576T1 (de) 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
DK1307263T3 (da) Hidtil ukendt anvendelse af lipaseinhibitorer
HUP0300061A3 (en) Use of il-18 inhibitors
DK1317421T3 (da) 2-amino-2-alkyl-5-heptensyre- og heptynsyrederivater der er nyttige som nitrogenoxidsynthaseinhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20031877D0 (no) Forebyggelse av korrosjon med fordelaktige biofilmer
EP1309552A4 (en) COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES
NO20024481D0 (no) Difluorbutyrsyre metalloproteaseinhibitorer
DK1130214T3 (da) Korrosionsinhibitorer
SI1337271T1 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
AU1212002A (en) Use of lipase inhibitors
DK1337271T3 (da) Kombination af GABA-agonister og sorbitoldehydrogenaseinhibitorer
DE60124221D1 (de) MONOHYDRAT DES CIS-LITHIUM-CYANO-4-i3-(CYCLOPENTYLOY)-4-METHOXYPHENYLöCYCLOHEXANCARBOXYLATS